U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H21NO2.ClH
Molecular Weight 295.804
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPRANOLOL HYDROCHLORIDE

SMILES

Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1

InChI

InChIKey=ZMRUPTIKESYGQW-UHFFFAOYSA-N
InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H21NO2
Molecular Weight 259.3434
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25198737 https://www.ncbi.nlm.nih.gov/pubmed/2865152

Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Propranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Also is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; for the prophylaxis of common migraine headache. In addition, is used to improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Due to the high penetration across the blood–brain barrier, propranolol causes sleep disturbances such as insomnia and vivid dreams, and nightmares. Dreaming (rapid eye movement sleep, REM) was reduced and increased awakening.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated for the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules are not indicated for the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of a common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Preventing
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
147 ng/mL
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
41 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
161 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
47 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
245 ng × h/mL
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
79 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.91 h
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.41 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely [IC50 >133 uM]
likely
likely
likely
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >1000 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
no
no
yes [Activation 28.1838 uM]
yes [IC50 189 uM]
yes [IC50 4 uM]
yes [Inhibition 5.5 uM]
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadminstration of CYP1A2 inhibitors increased Propranolol plasma concentration. Coadministration of CYP1A2 inducers decreased Propranolol plasma concentration.
Page: (Label) 5, 7-8
major
yes (co-administration study)
Comment: Coadminstration of CYP2D6 inhibitors increased Propranolol plasma concentration.
Page: (Label) 5, 7-8
minor
yes (co-administration study)
Comment: Coadminstration of CYP2C19 inhibitors increased Propranolol plasma concentration. Coadministration of CYP2C19 inducers decreased Propranolol plasma concentration.
Page: (Label) 5, 7-8
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
yes [Km 11.8 uM]
yes [Km 154 uM]
yes [Km 434 uM]
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Severe bradycardia after neostigmine in a patient taking propranolol to control paroxysmal atrial tachycardia.
1975 Feb
Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension.
1975 Oct 31
[Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)].
1976 Jul
The effect of sodium bicarbonate on propranolol-induced cardiovascular toxicity in a canine model.
2000
Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium.
2000 Aug
Low catecholamine concentrations protect adult rat ventricular myocytes against apoptosis through cAMP-dependent extracellular signal-regulated kinase activation.
2000 Dec
Beta-blockade in adriamycin-induced cardiomyopathy.
2000 Jun
Cerebellar Ataxia.
2000 May
Akathisia and exacerbation of psychopathology: a preliminary report.
2000 May-Jun
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000 Nov
Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters.
2000 Nov
Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.
2000 Oct
Functional assessment of skeletal muscle ventricles after pumping for up to four years in circulation.
2000 Oct
Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?
2000 Oct
Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation.
2000 Sep
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
2001 Feb
Idiopathic sustained left ventricular tachycardia in pediatric patients.
2001 Feb
Pharmacologic therapy for portal hypertension.
2001 Feb
Pharmacologic management of atrial fibrillation: current therapeutic strategies.
2001 Feb
Epinephrine yields translocation of lymphocytes to the lung.
2001 Feb
Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells.
2001 Feb
beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells.
2001 Feb
Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats.
2001 Feb
beta-Adrenoceptor and nNOS-derived NO interactions modulate hypoglycemic pial arteriolar dilation in rats.
2001 Feb
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.
2001 Feb 1
Comparison of spontaneous and noradrenaline-evoked non-selective cation channels in rabbit portal vein myocytes.
2001 Feb 1
Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality.
2001 Feb 13
Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists.
2001 Feb 16
Correlation of the electrical and intrinsic optical signals in the chicken spreading depression phenomenon.
2001 Feb 16
[Availability of antidotes in French emergency medical aid units].
2001 Feb 3
Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics.
2001 Jan
Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.
2001 Jan
Successful use of propranolol in migraine associated with electroconvulsive therapy.
2001 Jan
beta(1)-Adrenoceptors compensate for beta(3)-adrenoceptors in ileum from beta(3)-adrenoceptor knock-out mice.
2001 Jan
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
2001 Jan
Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study.
2001 Jan
Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants.
2001 Jan
Ventricular activation during sympathetic imbalance and its computational reconstruction.
2001 Jan
Adrenergic receptor activated ion transport in human fetal retinal pigment epithelium.
2001 Jan
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Role of PAG in the antinociception evoked from the medial or central amygdala in rats.
2001 Jan 1
Colon and anal sphincter contractions evoked by microstimulation of the sacral spinal cord in cats.
2001 Jan 19
Effect of carvedilol on atrioventricular conduction in the ischemic heart.
2001 Jan 26
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
2001 Jan 26
Ion-exchange fibers and drugs: an equilibrium study.
2001 Jan 29
Misrepresentation and miscommunication of teratogenic risk of drugs; analysis of three highly publicized international cases.
2001 Jan-Feb
Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis.
2001 Mar
Catecholamines increase lung edema clearance in rats with increased left atrial pressure.
2001 Mar
Erythroid carbonic anhydrase and hsp70 expression in chick embryonic development: role of cAMP and hypoxia.
2001 Mar
Central corticotropin releasing factor (CRF) and adrenergic receptors mediate hemodynamic responses to cocaine.
2001 Mar 2
Patents

Sample Use Guides

Hypertension: The usual initial dosage is 80 mg capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once. Angina Pectoris: Starting with 80 mg capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. Migraine: The initial oral dose is 80 mg capsules once daily. The usual effective dose range is 160 to 240 mg once daily. Hypertrophic Subaortic Stenosis: The usual dosage is 80 to 160 mg capsules once daily.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Propranolol dose-dependently inhibited growth factor-induced proliferation of cultured human umbilical vein endothelial cells (HUVECs) through a G₀/G₁ phase cell cycle arrest. This was correlated to decreased cyclin D1, cyclin D3, and cyclin-dependent kinase CDK6 protein levels, while increases in the CDK inhibitors p15(INK4B), p21(WAF1/Cip1) and p27(Kip1) were observed.
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:17:52 UTC 2023
Edited
by admin
on Thu Jul 06 02:17:52 UTC 2023
Record UNII
F8A3652H1V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPRANOLOL HYDROCHLORIDE
EP   HSDB   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
AY-64043
Code English
PROPRANALOL HYDROCHLORIDE, DL-
Common Name English
BEPRANE
Brand Name English
AVLOCARDYL
Brand Name English
PROPRANOLOL HYDROCHLORIDE [USP-RS]
Common Name English
HEMANGIOL
Brand Name English
2-PROPANOL, 1-((1-METHYLETHYL)AMINO)-3-(1-NAPHTHALENYLOXY)-, HYDROCHLORIDE, (±)-
Systematic Name English
PROPRANOLOL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
PROPRANOLOL HCL
Common Name English
INDERALICI
Brand Name English
Propranolol hydrochloride [WHO-DD]
Common Name English
PROPRANOLOLI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
ICI-45520
Code English
ICI 45520
Code English
OBSIDAN
Brand Name English
CARIDOLOL
Brand Name English
NSC-91523
Code English
PROPRANOLOL HYDROCHLORIDE [VANDF]
Common Name English
PROPRANOLOL HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
PROPRANOLOL HYDROCHLORIDE [JAN]
Common Name English
(±)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
Systematic Name English
PROPRANOLOL HYDROCHLORIDE [USAN]
Common Name English
INDERAL
Brand Name English
MONOPROLOL
Brand Name English
SUMIAL
Brand Name English
PROPRANOLOL HYDROCHLORIDE [MART.]
Common Name English
PROPRANOLOL HYDROCHLORIDE [WHO-IP]
Common Name English
INDOBLOC
Brand Name English
PROPRANOLOL HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
PYLAPRON
Brand Name English
BETACAP
Brand Name English
PROPRANOLOL HYDROCHLORIDE [HSDB]
Common Name English
INNOPRAN
Brand Name English
AY 64043
Code English
SLOPROLOL
Brand Name English
BEDRANOL
Brand Name English
DERALIN
Brand Name English
PROPRANOLOL HYDROCHLORIDE [MI]
Common Name English
APSOLOL
Brand Name English
ANAPRILIN
Brand Name English
DOCITON
Brand Name English
SERVANOLOL
Common Name English
HEMANGEOL
Brand Name English
TESNOL
Brand Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1841
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
FDA ORPHAN DRUG 454614
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
EMA ASSESSMENT REPORTS HEMANGIOL (AUHTORIZED: HEMANGIOMA)
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
NCI_THESAURUS C29576
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
Code System Code Type Description
CAS
3506-09-0
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
SUPERSEDED
NSC
91523
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
ChEMBL
CHEMBL27
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
DRUG BANK
DBSALT000549
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
SMS_ID
100000091292
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
DAILYMED
F8A3652H1V
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
RS_ITEM_NUM
1576005
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
CAS
318-98-9
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PROPRANOLOL HYDROCHLORIDE
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in water and in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antiadrenergic. Storage: Propranolol hydrochloride should be kept in a well-closed container, protected from light. Definition: Propranolol hydrochloride contains not less than 98.0% and not more than 101.0% of C16H21NO2,HCl, calculated with reference to the dried substance.
ECHA (EC/EINECS)
206-268-7
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-501-5
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
ALTERNATIVE
RXCUI
82084
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID3021198
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
HSDB
3176
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
PUBCHEM
62882
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
CAS
146874-86-4
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
SUPERSEDED
NCI_THESAURUS
C29382
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
EVMPD
SUB04091MIG
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
FDA UNII
F8A3652H1V
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY
MERCK INDEX
M9223
Created by admin on Thu Jul 06 02:17:52 UTC 2023 , Edited by admin on Thu Jul 06 02:17:52 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY